Scisparc Rule of 40
The Rule of 40 of Scisparc (SPRC) as of Oct 16, 2026 is -1,056.54 %. In the previous year, Rule of 40 was -614.82 % — a change of 71.84% (lower).
Get this data via API
Financial Data API
Rule of 40
-1,056.54 %
YoY
71.84%
Last updated:
Rule of 40 of Scisparc is 2025 -1,056.54 % . Rule of 40 of Scisparc was 2024 -614.82 % . It decreases by 71.84% lower compared to the previous year.
The Scisparc Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
-1,087.11 USD
Jan 1, 2019
-865.47 USD
Jan 1, 2020
-588.29 USD
Jan 1, 2021
-445.21 USD
Jan 1, 2022
-521.88 USD
Jan 1, 2023
-86.79 USD
Jan 1, 2024
-614.82 USD
Jan 1, 2025
-1,056.54 USD
| YEAR | Rule of 40 | YoY |
|---|---|---|
| -1,056.54 % | +71.84% | |
| -614.82 % | +608.43% | |
| -86.79 % | -83.37% | |
| -521.88 % | +17.22% | |
| -445.21 % | -24.32% | |
| -588.29 % | -32.03% | |
| -865.47 % | -20.39% | |
| -1,087.11 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Scisparc Stock analysis
What does Scisparc do? Scisparc Ltd., listed under the ticker SPRC with ISIN IL0010951403, is a biotechnology company headquartered in Tel Aviv-Yafo, Israel. The company operates in the healthcare sector and has a workforce of three employees. Scisparc Ltd. went public through an IPO on December 22, 2021. Its website is https://scisparc.com/. The company is engaged in the development of pharmaceutical products based on cannabinoid technologies, focusing on repurposing dronabinol for various medical conditions. Specific drug development programs include THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain treatment. Scisparc Ltd. is a clinical stage pharmaceutical company, indicating its focus on advancing drug candidates through clinical trials toward potential regulatory approval and commercialization. The company's activities are centered around leveraging cannabinoid-based approaches to address unmet medical needs in multiple therapeutic areas. Scisparc is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Scisparc stock
Rule of 40 of Scisparc is -1,056.54 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Scisparc since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Scisparc
All Key Metrics — Scisparc
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth